Trial Profile
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of ZSP1602 in Participants With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs ZSP 1602 (Primary)
- Indications Adenocarcinoma; Basal cell cancer; Gastric cancer; Glioblastoma; Medulloblastoma; Neuroendocrine tumours; Oesophageal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Guangdong Zhongsheng Pharmaceutical
- 20 Jul 2020 Planned End Date changed from 19 Dec 2020 to 31 Jul 2021.
- 20 Jul 2020 Planned primary completion date changed from 1 Nov 2020 to 31 Jul 2021.
- 18 Feb 2019 Status changed from not yet recruiting to recruiting.